Time

Event

7:30 am – Lobby Level

Registration Opens

7:30-8:45 am – 2nd Floor

Breakfast

7:30-8:45 am – 12th Floor

Investor Only Breakfast – Sponsored by Evotec
This breakfast is open to registered investors of BioFuture

8:00 am-12:00 pm – 2nd Floor

One-to-One Meetings

8:45-9:00 am – Roof

Welcome Remarks

Sara Jane Demy, Founder & CEO, Demy-Colton

9:00-9:55 am – Roof

Opening “Big Think" Plenary Session

Health as a Right vs. Health as a Business: Can Biopharma Do Both?
America needs a new and compelling vision if it is to continue its leadership in medical innovation—and biopharma must help shape that vision. The industry must confront the dynamic tension between health as a right and health as a business. Without shifting that narrative, we will continue to lose ground in both public opinion and the legislative debate.

Moderator:  

• Dennis Purcell, Founder & Senior Advisor, Aisling Capital 

Panel: 

• Paul Hastings, President & CEO, Nkarta
• Nouhad Husseini, Senior VP, BD & Corporate Strategy, Regeneron Pharmaceuticals, Inc.
• Alanna Temme, President, Midsized Biotech Alliance of America (MBAA)
• Priscilla VanderVeer, Executive Director, No Patient Left Behind (NPLB)

10:00-10:55 am – 12th Floor

Spotlight Panel 1A

BioFuture Now: Breakthroughs Shaping the Next Era of Biopharma Trailblazers
From the newest in molecular medicines and AI native discovery engines to connected medtech and platform companies— discuss what will be next across the life sciences. This group will highlight technologies that cut across oncology, CNS, metabolic disease, diagnostics, and beyond.

Moderator:

• Justin Walsh, Director, Research Analyst (Healthcare), JonesTrading Institutional Services, LLC

Panelists:

• Guido Gualdoni, CEO, Epitome Therapeutics FlexCo
• Andrew Altschuler, CEO, GOA Therapeutics
• Olga Granaturova, Co-Founder & President, Privebio, Inc.
• Jamie Oliver, Chief Medical Officer, Starton Therapeutics
• Kat Schmolly, CEO, zebraMD 

10:00-10:55 am – Roof

Spotlight Panel 1B

Immunity & Healthspan Unleashed: The Chronic Inflammation Connection
Companies at the intersection of immunology and longevity, tackling chronic inflammation as the shared driver of immune decline and aging, will showcase breakthrough platforms in immune engineering, precision immunomodulation, and regenerative medicine built to extend healthspan — the years lived in good health, not just years lived.

Moderator:

• Michael King Jr., Director, Research & Senior Biotechnology Analyst, Rodman & Renshaw

Panel:         

• Hans Keirstead, Chairman, Immunis, Inc.
• Yves Dudal, CEO, Perseo pharma AG
• Alexander Suvorov, CEO, ReGENE LLC    
• Nathan Stasko, CEO, Vast Therapeutics 

11:00-11:55 am– 12th Floor

Spotlight Panel 2A

Molecules & Machine Learning: The AI Drug Discovery Frontier
Hear from CEOs building AI-first platforms for target discovery, molecule design, and smarter R&D. Learn how AI is accelerating drug development, improving portfolio decisions, and creating the next generation of biotech value.

Moderator:

• Kyle Mikson, Managing Director, Senior Research Analyst, Canaccord Genuity

Panelists:

• Alexandra Sakatos, Co-Founder & CEO, Ancilia Biosciences
• Brent Vaughan, CEO & Co-Founder, Eratos Therapeutics, Inc.
• Dimi Kellari, CEO, Neion Bio
• Asad Ahmad, CEO & Co-Founder, Network Bio
• Akhila Kosaraju, CEO & Co-Founder, Phare Bio

11:00-11:55 am – Roof

Spotlight Panel 2B

The Breakthrough Effect: Where Medicine Goes Next
Executives advancing the frontier of biopharma and health innovation take the stage to share the breakthroughs driving their companies forward — what they discovered, why it changes the picture for patients, and what comes next. A first-hand look at the science stretching the boundaries of what is possible, told by the people advancing it.

Moderator:

• Boris Peaker, Managing Director, Healthcare Equity Research, JonesResearch Institutional Services

Panel:

• Myung Kim, CEO, Bilix
• David Jenkins, CSO, BioCryst
• Samuel Costello, CEO & Co-Founder, Biomebank
• Simon Mifsud, CEO & Co-Founder, Garland Surgical Ltd
• Howard Levy, CMO, Novapep 

12:00-1:00 pm – 2nd Floor

Networking Lunch

1:00 pm – 2nd Floor

One-to-One Meetings

1:00-1:55 pm – Roof

“Big Think" Plenary Session

Next Wave of Innovation: Navigating Policy and Regulatory Headwinds
Biopharma innovation is not slowing down—but the rules governing what it takes to bring a breakthrough to market are changing.  Washington and the regulatory environment are increasingly important drivers of biotech value. What policy shifts could accelerate, or derail, the next generation of innovation?

Moderator:

• Lori Ellis, Host, Open Door Salon

Panel:

• Cartier Esham, CEO, Esham Strategies, LLC
• Jennifer Hawks Bland, CEO, NewYorkBIO
• William Soliman, Founder & CEO, Accreditation Council for Medical Affairs (ACMA)
• Blake Wilson, Partner, Global Regulatory, Hogan Lovells Cadwalader
• Susan Winckler, CEO, Reagan-Udall Foundation

2:00-2:55 pm – 12th Floor

Spotlight Panel 3A

Beyond the Cure: The Brave New World of Revolutionary Cancer Therapeutics
Biotech CEOs redefining oncology on multiple frontiers will explore next generation cell therapies, AI enabled cancer drug discovery, and highly personalized oncology approaches powered by precision medicines and advanced platforms.

Moderator: 

• Edward Tenthoff, Senior Research Analyst, Piper Sandler

Panel:

• Wenzhi Tian, CEO & CSO, ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
• Robert Arch, CEO & President, Immunophotonics, Inc.
• Courtney Miller, CEO, Myosin Therapeutics
• Jennifer Cheng, CEO, PTM Therapeutics, Inc.
• Dori Thomas-Karyat, CEO, Synthis Therapeutics, Inc

2:00-2:55 pm – Roof

Spotlight Panel 3B

Where Technology & Code Meet Cells: Forging the MedTech & TechBio Future
Companies building at the live interface of hardware, software, and biology will explore AI powered diagnostics, physical AI, connected and implantable devices, programmable biology, and data driven care platforms that are redefining how we detect, treat, and optimize health.

Moderator:

Nehan Chatoor, Principal, Deerfield Management

Panel:

• Julie O’Shaugnessy, President, Conceivable Life Sciences
• Thakshila Liyanage, Co-Founder & CEO, Early is Good, Inc.   
• Jay Cormier, CEO & Founder, Eyedaptic
• Dede Willis, President & CEO, Orbit Genomics, Inc.
• Kwanyoung Park, Founder & CEO, WHITE TIGER GROUND

3:00-3:55 pm – Roof

“Big Think" Plenary Session

Enhancing the US Infrastructure for Drug Development
The USA has the science, talent, and capital to lead the next era of biopharma innovation. How can we strengthen clinical trials, data, manufacturing, and regulatory infrastructure to accelerate breakthroughs, attract investment, and keep the USA at the forefront of drug development?

Moderator:

• David Ewing Duncan, Journalist, Author, Researcher, Curator, & Advisor

Panel:

• Jennifer Cannon, Sector President, Commercial BioPharma Services, Thermo Fisher Scientific
• Nolan Townsend, CEO, Lexeo Therapeutics

4:00-4:55 pm – Roof

End of Day “Big Think" Plenary Session

Funding Has Come Back: But Has It?
Biotech financing has entered a new era. While capital is slowly returning to the sector, it is flowing selectively. This session will explore how today’s biotech leaders are navigating a more disciplined investment environment and what it takes to secure funding in the current market.

Moderator:

• William Kridel, Jr, Managing Director, Ferghana Partners 

Panel:  

• Scott Barry, Managing Director, EW Healthcare Partners
• Kevin Eisele, Managing Director, William Blair
• Robert Masella, Partner, Co-Chair, Public M&A, Life Sciences M&A, Goodwin
• Dennis Purcell, Founder & Senior Advisor, Aisling Capital

5:30-7:00 pm

Networking Reception

Barlume – 900 Broadway (20th Street)
Sponsored by Russo Partners